Wang JianQiu, Lan Longjiang, Ma Bingliang, Ren Gang, Yin ChengYi
Department of Otolaryngology, The First Affiliated Hospital, Huzhou University, The First People's Hospital of Huzhou, Huzhou 313000, Zhejiang, China.
Evid Based Complement Alternat Med. 2022 Oct 5;2022:6176043. doi: 10.1155/2022/6176043. eCollection 2022.
Laryngeal squamous cell carcinoma (LSCC) is a prevalent malignant tumor of the head and neck with a dismal prognosis. Keratin17 (KRT17) has been proven to serve as an oncogene in various cancers, but it has never been explored in LSCC. We proposed to assess the impact and possible mechanisms of KRT17 in the development of LSCC.
Quantitative reverse transcription-PCR (qRT-PCR) was utilized to examine the mRNA levels. The Kaplan-Meier method was used to calculate the relationship between KRT17 expression and survival curves in LSCC patients. Cell counting kit-8 (CCK-8), colony formation, and flow cytometry assays were utilized to estimate LSCC cell proliferation. The migration and invasion abilities of LSCC cells were ascertained by wound-healing and transwell assays. Immunohistochemical and western blot assays were utilized to appraise protein levels. The xenograft tumor model was used to determine the effect of KRT17 on tumor growth.
In the present study, KRT17 was extremely high in LSCC tissues and cells and correlated with a poor prognosis. Inhibition of KRT17 weakens cell proliferative, migratory, and invasive abilities in LSCC and contributes to cell cycle arrest. Besides, we approved that knockdown of KRT17 extraordinarily restrained the xenograft tumor growth in vivo. We preliminarily investigated the role of KRT17 on the AKT/mTOR and Wnt/-catenin signaling axes and found that these signaling pathways were largely blocked by KRT17 deletion.
Collectively, we uncovered that exhaustion of KRT17 suppresses LSCC progression through coordinating AKT/mTOR and Wnt/-catenin signaling axes, illustrating KRT17 as a promising biomarker for making strides in LSCC treatment.
喉鳞状细胞癌(LSCC)是一种常见的头颈部恶性肿瘤,预后较差。角蛋白17(KRT17)已被证明在多种癌症中作为癌基因发挥作用,但在LSCC中从未被研究过。我们旨在评估KRT17在LSCC发生发展中的作用及可能机制。
采用定量逆转录聚合酶链反应(qRT-PCR)检测mRNA水平。用Kaplan-Meier法计算KRT17表达与LSCC患者生存曲线之间的关系。利用细胞计数试剂盒-8(CCK-8)、集落形成和流式细胞术检测评估LSCC细胞增殖。通过伤口愈合和Transwell实验确定LSCC细胞的迁移和侵袭能力。采用免疫组织化学和蛋白质印迹实验评估蛋白质水平。利用异种移植肿瘤模型确定KRT17对肿瘤生长的影响。
在本研究中,KRT17在LSCC组织和细胞中表达极高,且与预后不良相关。抑制KRT17可减弱LSCC细胞的增殖、迁移和侵袭能力,并导致细胞周期停滞。此外,我们证实敲低KRT17可显著抑制体内异种移植肿瘤的生长。我们初步研究了KRT17在AKT/mTOR和Wnt/β-连环蛋白信号轴上的作用,发现这些信号通路在很大程度上被KRT17缺失所阻断。
总体而言,我们发现耗尽KRT17可通过协调AKT/mTOR和Wnt/β-连环蛋白信号轴抑制LSCC进展,说明KRT17是推动LSCC治疗取得进展的一个有前景的生物标志物。